Orphan Drug Consulting understand the shift in mindset required for a company to transition from a preclinical to clinical company. For many in the rare disease and innovator space, this change from a research-focused company into a clinical organization is further complicated by small patient sample sizes and complex product requirements. Orphan Drug Consulting support preclinical companies by: